- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
The Anglo-Swedish pharmaceutical giant announced that its drug used in combination with a common hormone therapy showed impressive results in stage three trials. Lynparza (also called
olaparib) was paired with abiraterone and was shown to slash the risk of disease progression by 34 percent compared to the normal standard of care. Since making this announcement,
AstraZeneca’s shares soared by five percent to £88.46 right after London market close. This comes after Astrazeneca hiked its dividend for the first time in 10 years this week after racking
up record sales from Covid vaccines. The company’s revenue soared 41 percent to £27.5billion last year, ramped up by almost £3billion in sales from its COVID-19 jab made with scientists from
Oxford University. According to analysts at Jefferies, the clinical trial success for prostate cancer has the potential to generate significant amounts of profit. They claimed that of the
30,000 to 50,000 patients suffering from the cancer in the US, there is a “significant commercial opportunity” of between £2.2billion to £3.7billion in sales. Susan Galbraith, Executive Vice
president of Oncology R&D at AstraZeneca, said: “This Lynparza combination has the potential to afford first-line patients more time without disease progression while also maintaining
their quality of life.” The drugs were reportedly well-tolerated. This means that patients could keep their quality of life, which is often impacted when trailing novel cancer treatments.
The phase III study was carried out by a team from the University of Montreal Hospital Center. It is set to be presented to the American Society of Clinical Oncology Genitourinary Cancers
Symposium on Thursday, February 17. Fred Saad, lead investigator of the trial, said: "It is clear to me that the prognosis for metastatic castration-resistant prostate cancer (mCRPC) is
extremely poor, and many patients are only able to receive one line of effective therapy. READ MORE: PUTIN STRIKES! RUSSIA CUTS GAS SUPPLY AFTER BIDEN'S TROOPS MAKE 'DE... In the
UK, one in eight people are diagnosed with the disease during their lifetime. Prostate Cancer UK says the disease kills over 11,500 lives every year. It is the most common cancer in men in
the UK, and the second most-common cancer in the world. But Cancer Research says that over 8 in 10 patients now survive the disease for 10 years or longer.
